ResMed (RMD) ebitda was $2.2B in FY2026 (+12% YoY). The tables below show the complete quarterly and annual ebitda history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual EBITDA
Fiscal Year
EBITDA
YoY
2026
$2.2B
+12%
2025
$2.0B
+20%
2024
$1.6B
+19%
2023
$1.4B
+12%
2022
$1.2B
+8%
2021
$1.1B
+11%
2020
$1.0B
+29%
2019
$792M
+9%
2018
$729M
+22%
2017
$596M
+5%
2016
$569M
+7%
2015
$530M
+0%
2014
$528M
+12%
2013
$471M
+15%
2012
$411M
+12%
2011
$368M
+11%
2010
$332M
+23%
2009
$270M
Recent Quarterly EBITDA
Quarter
EBITDA
Q2 2026
$521M
Q1 2026
$586M
Q4 2025
$576M
Q3 2025
$531M
Q2 2025
$543M
Q1 2025
$494M
Q4 2024
$486M
Q3 2024
$452M
Q2 2024
$446M
Q1 2024
$438M
Q4 2023
$404M
Q3 2023
$352M
Source: RMD on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.